Literature DB >> 91888

Site of Epstein-Barr virus replication in the oropharynx.

D G Morgan, J C Niederman, G Miller, H W Smith, J M Dowaliby.   

Abstract

Cells and cell-free material in saliva, parotid secretions, and throat washings from patients with acute infectious mononucleosis and patients undergoing tonsillectomy were assayed for the presence of infectious Epstein-Barr (EBV) virus. The agent was invariably present in cell-free form in saliva; neither infectious virus nor viral antigens were found in the cells. Tonsillar lymphocytes from eight patients were also free of EBV. In 10 of 40 patients virus was recovered in secretions from parotid-gland orifices or ducts. These findings suggest that the salivary glands are the site of EBV production in the oropharynx.

Entities:  

Mesh：

Year:  1979        PMID： 91888     DOI： 10.1016/s0140-6736(79)92384-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  25 in total

1.  Possible involvement of IL-12 expression by Epstein-Barr virus in Sjögren syndrome.

Authors:  M Horiuchi; S Yamano; H Inoue; J Ishii; Y Nagata; H Adachi; M Ono; J N Renard; F Mizuno; Y Hayashi; I Saito
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

2.  Identification of a protein encoded in the EB-viral open reading frame BMRF2.

Authors:  S Modrow; B Höflacher; H Wolf
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  Epstein-Barr virus infection of epithelial cells derived from primary cultures of adenoidal tissue.

Authors:  M Furukawa; H Sakashita; C Kato; R Umeda
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

4.  Strain-specific transcription and translation of the BamHI Z area of Epstein-Barr Virus.

Authors:  R Seibl; M Motz; H Wolf
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

5.  Persistence of Epstein-Barr virus in the parotid gland.

Authors:  H Wolf; M Haus; E Wilmes
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

6.  Prevention of Epstein-Barr virus-induced B-cell outgrowth by interferon alpha.

Authors:  J G Garner; M S Hirsch; R T Schooley
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

7.  LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.

Authors:  Gretchen L Bentz; Charles Randall Moss; Christopher B Whitehurst; Cary A Moody; Joseph S Pagano
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

8.  Epstein-Barr virus infection in carcinoma of the salivary gland.

Authors:  N Raab-Traub; P Rajadurai; K Flynn; A P Lanier
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

9.  Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis.

Authors:  Heather E Vezina; Henry H Balfour; Dennis R Weller; Bruce J Anderson; Richard C Brundage
Journal:  J Clin Pharmacol       Date:  2009-11-06       Impact factor: 3.126

10.  Heterogeneity of immune defects in three children with a chronic active Epstein-Barr virus infection.

Authors:  W Kuis; J J Roord; B J Zegers; A B Rickinson; J G Kapsenberg; H The; J W Stoop
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.